An interventional non-randomized trial to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.
Targeting Beta Cell Dysfunction in Longstanding T1D
Waking Beta Cells
Study Length: 8 weeks
Target Age/Sex: 18 – 50 years of age Male and Female
Participants will receive at no cost: study product, study materials and study-specific procedures